Literature DB >> 28167543

Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.

J Kristie Johnson1,2, Gwen L Robinson2, Lisa L Pineles2, Adebola O Ajao3, LiCheng Zhao4, Jennifer S Albrecht2, Anthony D Harris2, Kerri A Thom2, Jon P Furuno5.   

Abstract

Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae strains are increasing in prevalence worldwide. Carbapenem antibiotics are used as a first line of therapy against ESBL-producing Enterobacteriaceae We examined a cohort of critical care patients for gastrointestinal colonization with carbapenem-resistant ESBL-producing strains (CR-ESBL strains). We cultured samples from this cohort of patients for ESBL-producing Klebsiella spp. and Escherichia coli and then tested the first isolate from each patient for susceptibility to imipenem, doripenem, meropenem, and ertapenem. Multilocus sequence typing was performed on isolates that produced an ESBL and that were carbapenem resistant. Among all patients admitted to an intensive care unit (ICU), 4% were positive for an ESBL-producing isolate and 0.64% were positive for a CR-ESBL strain on surveillance culture. Among the first ESBL-producing E. coli and Klebsiella isolates from the patients' surveillance cultures, 11.2% were carbapenem resistant. Sequence type 14 (ST14), ST15, ST42, and ST258 were the dominant sequence types detected in this cohort of patients, with ST15 and ST258 steadily increasing in prevalence from 2006 to 2009. Patients colonized by a CR-ESBL strain were significantly more likely to receive antipseudomonal and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) therapy prior to ICU admission than patients colonized by carbapenem-susceptible ESBL-producing strains. They were also significantly more likely to have received a cephalosporin or a carbapenem antibiotic than patients colonized by carbapenem-susceptible ESBL-producing strains. In conclusion, in a cohort of patients residing in intensive care units within the United States, we found that 10% of the isolates were resistant to at least one carbapenem antibiotic. The continued emergence of carbapenem-resistant ESBL-producing strains is of significant concern, as infections due to these organisms are notoriously difficult to treat.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ESBL; MLST; carbapenem resistant

Mesh:

Substances:

Year:  2017        PMID: 28167543      PMCID: PMC5365708          DOI: 10.1128/AAC.01718-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms.

Authors:  Jessina C McGregor; Peter W Kim; Eli N Perencevich; Douglas D Bradham; Jon P Furuno; Keith S Kaye; Jeffrey C Fink; Patricia Langenberg; Mary-Claire Roghmann; Anthony D Harris
Journal:  Am J Epidemiol       Date:  2005-03-01       Impact factor: 4.897

Review 2.  Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli.

Authors:  Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

3.  Impact of freezing on the future utility of archived surveillance culture specimens.

Authors:  Heather P Green; Judith A Johnson; Jon P Furuno; Sandra M Strauss; Eli N Perencevich; Ebbing Lautenbach; Dong Lee; Anthony D Harris
Journal:  Infect Control Hosp Epidemiol       Date:  2007-05-31       Impact factor: 3.254

4.  Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting.

Authors:  Anthony D Harris; J Kristie Johnson; Kerri A Thom; Daniel J Morgan; Jessina C McGregor; Adebola O Ajao; Anita C Moore; Angela C Comer; Jon P Furuno
Journal:  Infect Control Hosp Epidemiol       Date:  2011-07       Impact factor: 3.254

5.  Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections.

Authors:  Jessina C McGregor; Eli N Perencevich; Jon P Furuno; Patricia Langenberg; Kathleen Flannery; Jingkun Zhu; Jeffrey C Fink; Douglas D Bradham; Anthony D Harris
Journal:  J Clin Epidemiol       Date:  2006-08-10       Impact factor: 6.437

Review 6.  ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients.

Authors:  E Tacconelli; M A Cataldo; S J Dancer; G De Angelis; M Falcone; U Frank; G Kahlmeter; A Pan; N Petrosillo; J Rodríguez-Baño; N Singh; M Venditti; D S Yokoe; B Cookson
Journal:  Clin Microbiol Infect       Date:  2014-01       Impact factor: 8.067

7.  Detection of the Klebsiella pneumoniae carbapenemase type 2 Carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid.

Authors:  J Kamile Rasheed; James W Biddle; Karen F Anderson; Laraine Washer; Carol Chenoweth; John Perrin; Duane W Newton; Jean B Patel
Journal:  J Clin Microbiol       Date:  2008-04-02       Impact factor: 5.948

8.  Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition.

Authors:  A D Harris; E N Perencevich; J K Johnson; D L Paterson; J G Morris; S M Strauss; J A Johnson
Journal:  Clin Infect Dis       Date:  2007-10-16       Impact factor: 9.079

9.  Risk of acquiring extended-spectrum β-lactamase-producing Klebsiella species and Escherichia coli from prior room occupants in the intensive care unit.

Authors:  Adebola O Ajao; J Kristie Johnson; Anthony D Harris; Min Zhan; Jessina C McGregor; Kerri A Thom; Jon P Furuno
Journal:  Infect Control Hosp Epidemiol       Date:  2013-05       Impact factor: 3.254

10.  Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action.

Authors:  Jean Carlet; Vincent Jarlier; Stephan Harbarth; Andreas Voss; Herman Goossens; Didier Pittet
Journal:  Antimicrob Resist Infect Control       Date:  2012-02-14       Impact factor: 4.887

View more
  5 in total

1.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

2.  Missense Mutations in the CrrB Protein Mediate Odilorhabdin Derivative Resistance in Klebsiella pneumoniae.

Authors:  Lucile Pantel; Paulo Juarez; Marine Serri; Lilia Boucinha; Emilie Lessoud; Anne Lanois; Alain Givaudan; Emilie Racine; Maxime Gualtieri
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

3.  Frequency of Beta-Lactamase Antibiotic Resistance Genes in Escherichia Coli and Klebsiella pneumoniae.

Authors:  Roghieh Golsha; Maryam Montazeri; Nazanin Razaghi; Mina Einollah Zade
Journal:  Ethiop J Health Sci       Date:  2021-05

4.  Colistin-phage combinations decrease antibiotic resistance in Acinetobacter baumannii via changes in envelope architecture.

Authors:  Xiaoqing Wang; Belinda Loh; Fernando Gordillo Altamirano; Yunsong Yu; Xiaoting Hua; Sebastian Leptihn
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

5.  Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90.

Authors:  Wei Zhang; Zhirong Li; Na Wang; Zhicong Yang; Jia Li; Caiqing Li; Xuying Han; Jinlu Liu; Liping Li; Shuwang Wang; Minghua Zhan
Journal:  Infect Drug Resist       Date:  2021-11-12       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.